PAVmed
PAVM
23 hedge funds and large institutions have $654K invested in PAVmed in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 0 closing their positions.
21% more funds holding
Funds holding: 19 → 23 (+4)
0.05% less ownership
Funds ownership: 0.36% → 0.31% (-0.05%)
53% less capital invested
Capital invested by funds: $1.38M → $654K (-$725K)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$98.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.6K |
| 3 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
+$10.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$2.19K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$798 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$197K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.98K |
| 3 |
BlackRock
New York
|
-$2.22K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$443 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$207 |
PAVM Hedge Fund Activity: Q4 2024 in Review
23 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q4 2024, worth a combined $654K — down 53% from $1.38M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PAVM positions and 0 closed out — a net gain of 5 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was First Manhattan, adding an estimated $98.5K. The largest seller was Vanguard Group, cutting an estimated $197K.
- 23 institutional investors held PAVmed (PAVM) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $654K of PAVmed stock for Q4 2024, down 53% quarter-over-quarter.
- 5 funds opened new PAVmed positions in Q4 2024 and 0 closed out, a net change of +5 holders.
- The largest PAVmed buyer in Q4 2024 was First Manhattan, an estimated $98.5K added.
- The largest PAVmed seller in Q4 2024 was Vanguard Group, an estimated $197K sold.
Based on aggregated 13F filings for Q4 2024.